Dosimetry during adjuvant 131I therapy in patients with differentiated thyroid cancer-clinical implications

Abstract The activity of radioiodine (131I) used in adjuvant therapy for thyroid cancer ranges between 30 mCi (1.1 GBq) and 150 mCi (5.5 GBq). Dosimetry based on Marinelli's formula, taking into consideration the absorbed dose in the postoperative tumour bed (D) should systematise the determina...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Piotr Szumowski, Saeid Abdelrazek, Dorota Iwanicka, Małgorzata Mojsak, Monika Sykała, Łukasz Żukowski, Katarzyna Siewko, Agnieszka Adamska, Katarzyna Maliszewska, Anna Popławska-Kita, Małgorzata Szelachowska, Adam Krętowski, Janusz Myśliwiec
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/53bc6359f80e42cdba7bf852ce594c13
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:53bc6359f80e42cdba7bf852ce594c13
record_format	dspace
spelling	oai:doaj.org-article:53bc6359f80e42cdba7bf852ce594c132021-12-02T18:34:20ZDosimetry during adjuvant 131I therapy in patients with differentiated thyroid cancer-clinical implications10.1038/s41598-021-93431-12045-2322https://doaj.org/article/53bc6359f80e42cdba7bf852ce594c132021-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-93431-1https://doaj.org/toc/2045-2322Abstract The activity of radioiodine (131I) used in adjuvant therapy for thyroid cancer ranges between 30 mCi (1.1 GBq) and 150 mCi (5.5 GBq). Dosimetry based on Marinelli's formula, taking into consideration the absorbed dose in the postoperative tumour bed (D) should systematise the determination of 131I activity. Retrospective analysis of 57 patients with differentiated thyroid cancer (DTC) after thyreidectomy and adjuvant 131I therapy with the fixed activity of 3.7 GBq. In order to calculate D from Marinelli's formula, the authors took into account, among other things, repeated dosimetry measurements (after 6, 24, and 72 h) made during scintigraphy and after administration of the therapeutic activity or radioiodine. In 75% of the patients, the values of D were > 300 Gy (i.e. above the value recommended by current guidelines). In just 16% of the patients, the obtained values fell between 250 and 300 Gy, whereas in 9% of the patients, the value of D was < 250 Gy. The therapy was successful for all the patients (stimulated Tg < 1 ng/ml and 131I uptake < 0.1% in the thyroid bed in follow-up examination). Dosimetry during adjuvant 131I therapy makes it possible to diversify the therapeutic activities of 131I in order to obtain a uniform value of D.Piotr SzumowskiSaeid AbdelrazekDorota IwanickaMałgorzata MojsakMonika SykałaŁukasz ŻukowskiKatarzyna SiewkoAgnieszka AdamskaKatarzyna MaliszewskaAnna Popławska-KitaMałgorzata SzelachowskaAdam KrętowskiJanusz MyśliwiecNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Piotr Szumowski Saeid Abdelrazek Dorota Iwanicka Małgorzata Mojsak Monika Sykała Łukasz Żukowski Katarzyna Siewko Agnieszka Adamska Katarzyna Maliszewska Anna Popławska-Kita Małgorzata Szelachowska Adam Krętowski Janusz Myśliwiec Dosimetry during adjuvant 131I therapy in patients with differentiated thyroid cancer-clinical implications
description	Abstract The activity of radioiodine (131I) used in adjuvant therapy for thyroid cancer ranges between 30 mCi (1.1 GBq) and 150 mCi (5.5 GBq). Dosimetry based on Marinelli's formula, taking into consideration the absorbed dose in the postoperative tumour bed (D) should systematise the determination of 131I activity. Retrospective analysis of 57 patients with differentiated thyroid cancer (DTC) after thyreidectomy and adjuvant 131I therapy with the fixed activity of 3.7 GBq. In order to calculate D from Marinelli's formula, the authors took into account, among other things, repeated dosimetry measurements (after 6, 24, and 72 h) made during scintigraphy and after administration of the therapeutic activity or radioiodine. In 75% of the patients, the values of D were > 300 Gy (i.e. above the value recommended by current guidelines). In just 16% of the patients, the obtained values fell between 250 and 300 Gy, whereas in 9% of the patients, the value of D was < 250 Gy. The therapy was successful for all the patients (stimulated Tg < 1 ng/ml and 131I uptake < 0.1% in the thyroid bed in follow-up examination). Dosimetry during adjuvant 131I therapy makes it possible to diversify the therapeutic activities of 131I in order to obtain a uniform value of D.
format	article
author	Piotr Szumowski Saeid Abdelrazek Dorota Iwanicka Małgorzata Mojsak Monika Sykała Łukasz Żukowski Katarzyna Siewko Agnieszka Adamska Katarzyna Maliszewska Anna Popławska-Kita Małgorzata Szelachowska Adam Krętowski Janusz Myśliwiec
author_facet	Piotr Szumowski Saeid Abdelrazek Dorota Iwanicka Małgorzata Mojsak Monika Sykała Łukasz Żukowski Katarzyna Siewko Agnieszka Adamska Katarzyna Maliszewska Anna Popławska-Kita Małgorzata Szelachowska Adam Krętowski Janusz Myśliwiec
author_sort	Piotr Szumowski
title	Dosimetry during adjuvant 131I therapy in patients with differentiated thyroid cancer-clinical implications
title_short	Dosimetry during adjuvant 131I therapy in patients with differentiated thyroid cancer-clinical implications
title_full	Dosimetry during adjuvant 131I therapy in patients with differentiated thyroid cancer-clinical implications
title_fullStr	Dosimetry during adjuvant 131I therapy in patients with differentiated thyroid cancer-clinical implications
title_full_unstemmed	Dosimetry during adjuvant 131I therapy in patients with differentiated thyroid cancer-clinical implications
title_sort	dosimetry during adjuvant 131i therapy in patients with differentiated thyroid cancer-clinical implications
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/53bc6359f80e42cdba7bf852ce594c13
work_keys_str_mv	AT piotrszumowski dosimetryduringadjuvant131itherapyinpatientswithdifferentiatedthyroidcancerclinicalimplications AT saeidabdelrazek dosimetryduringadjuvant131itherapyinpatientswithdifferentiatedthyroidcancerclinicalimplications AT dorotaiwanicka dosimetryduringadjuvant131itherapyinpatientswithdifferentiatedthyroidcancerclinicalimplications AT małgorzatamojsak dosimetryduringadjuvant131itherapyinpatientswithdifferentiatedthyroidcancerclinicalimplications AT monikasykała dosimetryduringadjuvant131itherapyinpatientswithdifferentiatedthyroidcancerclinicalimplications AT łukaszzukowski dosimetryduringadjuvant131itherapyinpatientswithdifferentiatedthyroidcancerclinicalimplications AT katarzynasiewko dosimetryduringadjuvant131itherapyinpatientswithdifferentiatedthyroidcancerclinicalimplications AT agnieszkaadamska dosimetryduringadjuvant131itherapyinpatientswithdifferentiatedthyroidcancerclinicalimplications AT katarzynamaliszewska dosimetryduringadjuvant131itherapyinpatientswithdifferentiatedthyroidcancerclinicalimplications AT annapopławskakita dosimetryduringadjuvant131itherapyinpatientswithdifferentiatedthyroidcancerclinicalimplications AT małgorzataszelachowska dosimetryduringadjuvant131itherapyinpatientswithdifferentiatedthyroidcancerclinicalimplications AT adamkretowski dosimetryduringadjuvant131itherapyinpatientswithdifferentiatedthyroidcancerclinicalimplications AT januszmysliwiec dosimetryduringadjuvant131itherapyinpatientswithdifferentiatedthyroidcancerclinicalimplications
_version_	1718377860205379584

Dosimetry during adjuvant 131I therapy in patients with differentiated thyroid cancer-clinical implications

Ejemplares similares